ப்ரிந்ஸிபல் இல் மூலையில் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரிந்ஸிபல் இல் மூலையில் ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரிந்ஸிபல் இல் மூலையில் ஆராய்ச்சி Today - Breaking & Trending Today

EU: Advantages and Disadvantages of Digital Gatekeeping


GAFA – Google, Amazon, Facebook, and Apple – and the inability of
ex post enforcement of competition law to prevent potential anticompetitive conduct by these firms.
[2] Several European jurisdictions are currently considering an overhaul of their competition policy approach towards dominant companies in the digital economy. A common theme is that competition authorities or newly created
digital markets agencies could be given the power to regulate dominant companies with a
gatekeeper
status. As an important first step in this new regulatory approach, policymakers in various jurisdictions have specified the criteria for identifying the firms, or
gatekeepers, that are to be subject to regulation. ....

New York , United States , United Kingdom , City Of , San Francisco , Natasha Lomas , Marc Rysman , Rima Alaily , Vivek Mani , Jason Furman , Philipp Bongartz , Michael Katz , Lapo Filistrucchi , Council On Contestable , Cartel Office , Professor Of Economics At Boston University , App Store Principles To Promote Choice , Regulation Of The European Parliament , Competition Policy International , American Express , European Commission , Cartel Office Bundeskartellamt , American Express Co , Supreme Court , Principal At Cornerstone Research , New York Times ,

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer


Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
December 17, 2020 08:00 ET
| Source:
Spero Therapeutics, Inc.
Spero Therapeutics, Inc.
Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
“Sath is an ideal fit for our management team given his experience leading financial strategy and executing within both clinical and commercial stage companies,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “He has extensive strat ....

United Kingdom , Ankit Mahadevia , Stephen Dipalma , Satyavrat Sath Shukla , Yale University , Ziopharm Oncology Inc , Exchange Commission , Principal At Cornerstone Research , Harvard University , Spero Therapeutics Inc , Hayes Bartlett Inc , Compensation Committee Of Spero Board Directors , Chief Financial Officer , Chief Executive Officer , Interim Chief Financial Officer , Ziopharm Oncology , Vice President , Global Head , Corporate Finance , Vertex Pharmaceuticals , Cornerstone Research , Chartered Financial Analyst , Compensation Committee , Spero Therapeutics , Equity Incentive Plan , Nasdaq Listing Rule ,

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer


Published: Dec 17, 2020
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Spero Therapeutics Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
“Sath is an ideal fit for our management team given his experience leading financial strategy and executing within both clinical and commercial stage companies,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “He has extensive strategic and financial expertise, which will be instrumental in helping us to drive corporate growth through the potential commercialization of tebipenem HBr and the clinical advancement of SPR720 and SPR206. We are excited to welcome Sath to Spero and are ....

United Kingdom , Ankit Mahadevia , Stephen Dipalma , Satyavrat Sath Shukla , Yale University , Ziopharm Oncology Inc , Exchange Commission , Principal At Cornerstone Research , Harvard University , Spero Therapeutics Inc , Hayes Bartlett Inc , Compensation Committee Of Spero Board Directors , Chief Financial Officer , Chief Executive Officer , Interim Chief Financial Officer , Ziopharm Oncology , Vice President , Global Head , Corporate Finance , Vertex Pharmaceuticals , Cornerstone Research , Chartered Financial Analyst , Compensation Committee , Spero Therapeutics , Equity Incentive Plan , Nasdaq Listing Rule ,